Free Trial
→ 9 days. (From Behind the Markets) (Ad)tc pixel Free DXRX Stock Alerts

Diaceutics (DXRX) Competitors

Diaceutics logo
GBX 144.88 -8.12 (-5.31%)
As of 11:06 AM Eastern
Compare

DXRX vs. IDHC, ABDX, GDR, YGEN, and GENI

Should you buy Diaceutics stock or one of its competitors? MarketBeat compares Diaceutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Diaceutics include Integrated Diagnostics (IDHC), Abingdon Health (ABDX), genedrive (GDR), Yourgene Health (YGEN), and GENinCode (GENI). These companies are all part of the "diagnostics & research" industry.

How does Diaceutics compare to Integrated Diagnostics?

Integrated Diagnostics (LON:IDHC) and Diaceutics (LON:DXRX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, valuation, risk, institutional ownership, analyst recommendations and earnings.

Integrated Diagnostics has a beta of 0.355, meaning that its stock price is 65% less volatile than the broader market. Comparatively, Diaceutics has a beta of 0.92, meaning that its stock price is 8% less volatile than the broader market.

In the previous week, Diaceutics had 1 more articles in the media than Integrated Diagnostics. MarketBeat recorded 1 mentions for Diaceutics and 0 mentions for Integrated Diagnostics. Integrated Diagnostics' average media sentiment score of 0.00 equaled Diaceutics'average media sentiment score.

Company Overall Sentiment
Integrated Diagnostics Neutral
Diaceutics Neutral

Diaceutics has a consensus target price of GBX 205.33, suggesting a potential upside of 39.68%. Given Diaceutics' stronger consensus rating and higher probable upside, analysts plainly believe Diaceutics is more favorable than Integrated Diagnostics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Integrated Diagnostics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Diaceutics
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

Integrated Diagnostics has higher revenue and earnings than Diaceutics. Integrated Diagnostics is trading at a lower price-to-earnings ratio than Diaceutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Integrated Diagnostics£8.35B0.00£4.01T£250.030.00
Diaceutics£38.44M3.24-£2.84M£0.111,336.36

Integrated Diagnostics has a net margin of 17.46% compared to Diaceutics' net margin of 0.25%. Integrated Diagnostics' return on equity of 42.26% beat Diaceutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Integrated Diagnostics17.46% 42.26% 9.69%
Diaceutics 0.25%0.25%-6.06%

7.7% of Integrated Diagnostics shares are held by institutional investors. Comparatively, 32.7% of Diaceutics shares are held by institutional investors. 28.0% of Integrated Diagnostics shares are held by company insiders. Comparatively, 26.3% of Diaceutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Diaceutics beats Integrated Diagnostics on 8 of the 15 factors compared between the two stocks.

How does Diaceutics compare to Abingdon Health?

Abingdon Health (LON:ABDX) and Diaceutics (LON:DXRX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and risk.

Diaceutics has a consensus target price of GBX 205.33, suggesting a potential upside of 39.68%. Given Diaceutics' stronger consensus rating and higher probable upside, analysts clearly believe Diaceutics is more favorable than Abingdon Health.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Abingdon Health
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Diaceutics
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

Diaceutics has a net margin of 0.25% compared to Abingdon Health's net margin of -33.88%. Diaceutics' return on equity of 0.25% beat Abingdon Health's return on equity.

Company Net Margins Return on Equity Return on Assets
Abingdon Health-33.88% -55.91% -17.93%
Diaceutics 0.25%0.25%-6.06%

In the previous week, Abingdon Health and Abingdon Health both had 1 articles in the media. Abingdon Health's average media sentiment score of 0.00 equaled Diaceutics'average media sentiment score.

Company Overall Sentiment
Abingdon Health Neutral
Diaceutics Neutral

Abingdon Health has higher earnings, but lower revenue than Diaceutics. Abingdon Health is trading at a lower price-to-earnings ratio than Diaceutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Abingdon Health£9.57M3.41-£796.37K-£0.81N/A
Diaceutics£38.44M3.24-£2.84M£0.111,336.36

3.7% of Abingdon Health shares are owned by institutional investors. Comparatively, 32.7% of Diaceutics shares are owned by institutional investors. 8.0% of Abingdon Health shares are owned by insiders. Comparatively, 26.3% of Diaceutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Abingdon Health has a beta of 0.117, suggesting that its share price is 88% less volatile than the broader market. Comparatively, Diaceutics has a beta of 0.92, suggesting that its share price is 8% less volatile than the broader market.

Summary

Diaceutics beats Abingdon Health on 12 of the 14 factors compared between the two stocks.

How does Diaceutics compare to genedrive?

genedrive (LON:GDR) and Diaceutics (LON:DXRX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, media sentiment, institutional ownership, earnings and risk.

Diaceutics has higher revenue and earnings than genedrive. genedrive is trading at a lower price-to-earnings ratio than Diaceutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
genedrive£929K23.33-£21.22M-£0.79N/A
Diaceutics£38.44M3.24-£2.84M£0.111,336.36

0.1% of genedrive shares are owned by institutional investors. Comparatively, 32.7% of Diaceutics shares are owned by institutional investors. 4.9% of genedrive shares are owned by company insiders. Comparatively, 26.3% of Diaceutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Diaceutics has a consensus price target of GBX 205.33, suggesting a potential upside of 39.68%. Given Diaceutics' stronger consensus rating and higher possible upside, analysts plainly believe Diaceutics is more favorable than genedrive.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
genedrive
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Diaceutics
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

genedrive has a beta of -0.04, indicating that its share price is 104% less volatile than the broader market. Comparatively, Diaceutics has a beta of 0.92, indicating that its share price is 8% less volatile than the broader market.

In the previous week, Diaceutics had 1 more articles in the media than genedrive. MarketBeat recorded 1 mentions for Diaceutics and 0 mentions for genedrive. genedrive's average media sentiment score of 0.00 equaled Diaceutics'average media sentiment score.

Company Overall Sentiment
genedrive Neutral
Diaceutics Neutral

Diaceutics has a net margin of 0.25% compared to genedrive's net margin of -500.75%. Diaceutics' return on equity of 0.25% beat genedrive's return on equity.

Company Net Margins Return on Equity Return on Assets
genedrive-500.75% -1,044.57% -74.09%
Diaceutics 0.25%0.25%-6.06%

Summary

Diaceutics beats genedrive on 14 of the 15 factors compared between the two stocks.

How does Diaceutics compare to Yourgene Health?

Yourgene Health (LON:YGEN) and Diaceutics (LON:DXRX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, media sentiment, dividends, profitability and analyst recommendations.

Diaceutics has higher revenue and earnings than Yourgene Health. Yourgene Health is trading at a lower price-to-earnings ratio than Diaceutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Yourgene Health£29.67M0.00-£8.17M-£0.01N/A
Diaceutics£38.44M3.24-£2.84M£0.111,336.36

Diaceutics has a consensus price target of GBX 205.33, indicating a potential upside of 39.68%. Given Diaceutics' stronger consensus rating and higher probable upside, analysts clearly believe Diaceutics is more favorable than Yourgene Health.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Yourgene Health
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Diaceutics
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Diaceutics had 1 more articles in the media than Yourgene Health. MarketBeat recorded 1 mentions for Diaceutics and 0 mentions for Yourgene Health. Yourgene Health's average media sentiment score of 0.00 equaled Diaceutics'average media sentiment score.

Company Overall Sentiment
Yourgene Health Neutral
Diaceutics Neutral

Diaceutics has a net margin of 0.25% compared to Yourgene Health's net margin of -27.55%. Diaceutics' return on equity of 0.25% beat Yourgene Health's return on equity.

Company Net Margins Return on Equity Return on Assets
Yourgene Health-27.55% -27.06% -6.71%
Diaceutics 0.25%0.25%-6.06%

23.3% of Yourgene Health shares are held by institutional investors. Comparatively, 32.7% of Diaceutics shares are held by institutional investors. 64.4% of Yourgene Health shares are held by company insiders. Comparatively, 26.3% of Diaceutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Yourgene Health has a beta of 0.86, meaning that its stock price is 14% less volatile than the broader market. Comparatively, Diaceutics has a beta of 0.92, meaning that its stock price is 8% less volatile than the broader market.

Summary

Diaceutics beats Yourgene Health on 13 of the 14 factors compared between the two stocks.

How does Diaceutics compare to GENinCode?

GENinCode (LON:GENI) and Diaceutics (LON:DXRX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, profitability, risk and institutional ownership.

GENinCode has a beta of 0.608, suggesting that its stock price is 39% less volatile than the broader market. Comparatively, Diaceutics has a beta of 0.92, suggesting that its stock price is 8% less volatile than the broader market.

Diaceutics has a net margin of 0.25% compared to GENinCode's net margin of -170.49%. Diaceutics' return on equity of 0.25% beat GENinCode's return on equity.

Company Net Margins Return on Equity Return on Assets
GENinCode-170.49% -262.16% -63.99%
Diaceutics 0.25%0.25%-6.06%

Diaceutics has a consensus price target of GBX 205.33, suggesting a potential upside of 39.68%. Given Diaceutics' stronger consensus rating and higher probable upside, analysts clearly believe Diaceutics is more favorable than GENinCode.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GENinCode
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Diaceutics
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

4.8% of GENinCode shares are held by institutional investors. Comparatively, 32.7% of Diaceutics shares are held by institutional investors. 8.6% of GENinCode shares are held by company insiders. Comparatively, 26.3% of Diaceutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, GENinCode and GENinCode both had 1 articles in the media. GENinCode's average media sentiment score of 0.00 equaled Diaceutics'average media sentiment score.

Company Overall Sentiment
GENinCode Neutral
Diaceutics Neutral

Diaceutics has higher revenue and earnings than GENinCode. GENinCode is trading at a lower price-to-earnings ratio than Diaceutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GENinCode£2.91M2.80-£6.10M-£2.35N/A
Diaceutics£38.44M3.24-£2.84M£0.111,336.36

Summary

Diaceutics beats GENinCode on 14 of the 14 factors compared between the two stocks.

Get Diaceutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for DXRX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

DXRX vs. The Competition

Export
MetricDiaceuticsDiagnostics & Research IndustryMedical SectorLON Exchange
Market Cap£124.41M£44.09M£6.42B£2.77B
Dividend YieldN/A3.34%2.69%6.12%
P/E Ratio1,336.3680.4723.80364.62
Price / Sales3.24641.50527.6787,474.37
Price / Cash3.1211.4241.3427.85
Price / Book3.203.699.997.73
Net Income-£2.84M£334.07B£3.56B£5.89B
7 Day Performance3.52%1.41%-1.18%0.09%
1 Year Performance12.39%10.35%28.52%74.58%

Diaceutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DXRX
Diaceutics
1.8297 of 5 stars		GBX 144.88
-5.3%		GBX 205.33
+41.7%		+20.9%£122.61M£38.44M1,317.09151
IDHC
Integrated Diagnostics
N/AGBX 0.59
-0.3%		N/A+61.1%£341.82M£8.35B0.006,692
ABDX
Abingdon Health
N/AGBX 11.02
-4.2%		N/A+89.9%£28.87M£9.57MN/A84
GDR
genedrive
N/AGBX 1.15
+4.1%		N/A-13.5%£17.66M£929KN/A43
YGEN
Yourgene Health
N/AN/AN/AN/A£16.43M£29.67MN/A253

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:DXRX) was last updated on 6/4/2026 by MarketBeat.com Staff.
From Our Partners
Nevada gold explorer near Kinross district draws attention
Gold has surged past $5,300 per ounce, with Goldman Sachs and JPMorgan forecasting $6,000+ by end of 2026. Cen...
Wall Street Logic | Sponsoredtc pixel
Trump’s New Dollar revealed
The last time something like this happened was 1974 - a secret deal that quietly determined the financial fate...
Porter & Company | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
How to claim a stake in SpaceX before the June 12 IPO
SpaceX is expected to go public on June 12 - and for the first time, everyday investors may have a way in befo...
Brownstone Research | Sponsoredtc pixel
The SpaceX S-1 changes everything
SpaceX just filed its IPO paperwork. And buried inside that filing was something that should change how every ...
Crypto 101 Media | Sponsoredtc pixel
Oil is settling in yuan now - here's what that means for gold
Saudi Arabia has terminated its 1974 petrodollar agreement with the United States - the deal that forced every...
Golden Portfolio | Sponsoredtc pixel
The chokepoint supplier behind SpaceX's $1.75 trillion empire
When Musk laughed and said 'you need transformers to run transformers,' it wasn't a joke - it was a confession...
Behind the Markets | Sponsoredtc pixel
Washington just moved up the "go broke" date on Social Security
The Congressional Budget Office just moved up Social Security's trust fund depletion date to 2032 - a full yea...
Investors Alley | Sponsoredtc pixel